Inactief instrument

Andere talen Avalanche Biotechnologies Inc Nasdaq

Aandelen

US05337G1076

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	15/05
Adverum Biotechnologies: Q1 Earnings Snapshot	09/05
Adverum Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights	09/05
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences	06/05
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences	03/05
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting	25/04
Adverum Biotechnologies Files $200 Million Mixed Shelf	21/03
Adverum Biotechnologies: Q4 Earnings Snapshot	18/03
Adverum Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Adverum Biotechnologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates	18/03
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference	28/02
Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors	21/02
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	12/02
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD	08/02
Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD	08/02
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	05/02
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing	05/02
Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors	05/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Avalanche Biotechnologies Inc Nasdaq

Aandelen

US05337G1076

Andere talen

Filters